Comparative Pharmacology
Head-to-head clinical analysis: ALOCRIL versus ALOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOCRIL versus ALOMIDE.
ALOCRIL vs ALOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer that inhibits the release of inflammatory mediators (e.g., histamine, leukotrienes) from conjunctival mast cells. Also inhibits eosinophil chemotaxis and activation.
Lodoxamide stabilizes mast cells by preventing antigen-induced release of histamine and other inflammatory mediators (e.g., SRS-A) from the mast cell, possibly by inhibiting calcium influx.
2 drops in each eye four times daily; ophthalmic route.
1 to 2 drops in each affected eye four times daily (every 6 hours).
None Documented
None Documented
8.6 hours (terminal elimination half-life in healthy adults; may be prolonged in renal impairment, e.g., up to 18 hours in patients with severe renal dysfunction).
Terminal elimination half-life is approximately 1.5-2 hours. Clinically, this short half-life supports frequent dosing for sustained ocular effects.
Renal (primarily unchanged drug; approximately 50-60% excreted unchanged in urine within 48 hours). Biliary/fecal elimination accounts for <10%.
Primarily renal excretion; approximately 50-60% of the dose is excreted unchanged in urine within 24 hours. Fecal elimination accounts for less than 10%. Minor biliary excretion.
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer